aTyr Pharma, Inc. (ATYR)
NASDAQ: ATYR · IEX Real-Time Price · USD
1.650
-0.120 (-6.78%)
Jun 18, 2024, 4:00 PM EDT - Market closed
aTyr Pharma Revenue
aTyr Pharma had revenue of $588.00K in the twelve months ending March 31, 2024, down -94.34% year-over-year. Revenue in the quarter ending March 31, 2024 was $235.00K. In the year 2023, aTyr Pharma had annual revenue of $353.00K, a decrease of -96.60%.
Revenue (ttm)
$588.00K
Revenue Growth
-94.34%
P/S Ratio
193.65
Revenue / Employee
$10,500
Employees
56
Market Cap
113.87M
Revenue Chart
* The company reports in USD currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 353.00K | -10.03M | -96.60% |
Dec 31, 2022 | 10.39M | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 10.46M | 10.03M | 2,377.49% |
Dec 31, 2019 | 422.00K | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Karyopharm Therapeutics | 140.46M |
Seres Therapeutics | 126.85M |
Electromed | 53.50M |
Adagene | 18.11M |
Veru Inc. | 13.48M |
ATYR News
- 15 days ago - aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR” - GlobeNewsWire
- 25 days ago - aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference - GlobeNewsWire
- 5 weeks ago - aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis - GlobeNewsWire
- 6 weeks ago - aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - aTyr Pharma to Participate in April Investor Conferences - GlobeNewsWire
- 3 months ago - aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results - GlobeNewsWire